Superselective Intra-Arterial Cerebral Infusion of Novel Agents After Blood-Brain Disruption for the Treatment of Recurrent Glioblastoma Multiforme: A Technical Case Series

Neurosurgery Clinics of North America

Volumn 23, Issue 2, 2012, Pages 323-329

  Shin, Benjamin J ^a   Burkhardt, Jan Karl ^a   Riina, Howard A ^a   Boockvar, John A ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Bevacizumab; Cetuximab; Glioblastoma multiforme; Intra arterial chemotherapy; Temozolomide

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUORODEOXYGLUCOSE F 18; IRINOTECAN; MANNITOL; TEMOZOLOMIDE;

ADULT; BLOOD BRAIN BARRIER; BRAIN SURGERY; CANCER GRADING; CANCER RADIOTHERAPY; CASE REPORT; CONTINUOUS INFUSION; CRANIOTOMY; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG TUMOR LEVEL; FEMALE; FOLLOW UP; GAMMA KNIFE RADIOSURGERY; GLIOBLASTOMA; HUMAN; MALE; MEMBRANE PERMEABILITY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; DACARBAZINE; FEMALE; GLIOBLASTOMA; HUMANS; INFUSIONS, INTRA-ARTERIAL; MALE; MANNITOL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; TREATMENT OUTCOME;

EID: 84858605001     PISSN: 10423680     EISSN: 15581349     Source Type: Journal    
DOI: 10.1016/j.nec.2012.01.008     Document Type: Review

References (22)

1. Hess K.R., Broglio K.R., Bondy M.L. Adult glioma incidence trends in the United States, 1977-2000. Cancer 2004, 101:2293.
2. Davis F.G., Freels S., Grutsch J., et al. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J Neurosurg 1998, 88:1.
3. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987.
4. Khasraw M., Lassman A.B. Advances in the treatment of malignant gliomas. Curr Oncol Rep 2010, 12:26.
5. Buie L.W., Valgus J. Bevacizumab: a treatment option for recurrent glioblastoma multiforme. Ann Pharmacother 2008, 42:1486.
6. Sampson J.H., Archer G.E., Mitchell D.A., et al. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther 2009, 8:2773.
7. Boockvar J.A., Tsiouris A.J., Hofstetter C.P., et al. Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. Clinical article. J Neurosurg 2011, 114:624.
8. Hochberg F.H., Pruitt A.A., Beck D.O., et al. The rationale and methodology for intra-arterial chemotherapy with BCNU as treatment for glioblastoma. J Neurosurg 1985, 63:876.
9. Ashby L.S., Shapiro W.R. Intra-arterial cisplatin plus oral etoposide for the treatment of recurrent malignant glioma: a phase II study. J Neurooncol 2001, 51:67.
10. Shapiro W.R., Green S.B., Burger P.C., et al. A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J Neurosurg 1992, 76:772.
11. Silvani A., Eoli M., Salmaggi A., et al. Intra-arterial ACNU and carboplatin versus intravenous chemotherapy with cisplatin and BCNU in newly diagnosed patients with glioblastoma. Neurol Sci 2002, 23:219.
12. Hasegawa H., Allen J.C., Mehta B.M., et al. Enhancement of CNS penetration of methotrexate by hyperosmolar intracarotid mannitol or carcinomatous meningitis. Neurology 1979, 29:1280.
13. Neuwelt E.A., Howieson J., Frenkel E.P., et al. Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement by blood-brain barrier modification in glioblastoma. Neurosurgery 1986, 19:573.
14. Van Cutsem E., Kohne C.H., Hitre E., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 360:1408.
15. Vredenburgh J.J., Desjardins A., Herndon J.E., et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007, 25:4722.
16. van den Bent M.J., Brandes A.A., Rampling R., et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol 2009, 27:1268.
17. Riina H.A., Fraser J.F., Fralin S., et al. Superselective intraarterial cerebral infusion of bevacizumab: a revival of interventional neuro-oncology for malignant glioma. J Exp Ther Oncol 2009, 8:145.
18. Namba H., Kobayashi S., Iwadate Y., et al. Assessment of the brain areas perfused by superselective intra-arterial chemotherapy using single photon emission computed tomography with technetium-99m-hexamethyl-propyleneamine oxime: technical note. Neurol Med Chir (Tokyo) 1994, 34:832.
19. Neuwelt E.A., Specht H.D., Barnett P.A., et al. Increased delivery of tumor-specific monoclonal antibodies to brain after osmotic blood-brain barrier modification in patients with melanoma metastatic to the central nervous system. Neurosurgery 1987, 20:885.
20. Sarin H., Kanevsky A.S., Wu H., et al. Physiologic upper limit of pore size in the blood-tumor barrier of malignant solid tumors. J Transl Med 2009, 7:51.
21. Calabrese C., Poppleton H., Kocak M., et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007, 11:69.
22. Wang R., Chadalavada K., Wilshire J., et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010, 468:829.